Insulin PP

Diabetes

Report in 4Hrs

At Home

No Fasting Required

Details

Assesses insulin levels in blood; used in diagnosing insulin resistance and metabolic syndrome.

₹229₹770

70% OFF

Insulin PP - Comprehensive Medical Test Information Guide

Why is it done?
- Measures insulin levels 2 hours after consuming a standardized glucose load or meal to assess postprandial (after-eating) insulin secretion and response
- Evaluates pancreatic beta cell function and insulin secretory capacity in response to glucose stimulation
- Screens for insulin resistance and metabolic syndrome in patients with suspected or known prediabetes or type 2 diabetes
- Investigates hyperglycemic episodes and abnormal glucose tolerance test results
- Assesses risk for cardiovascular disease associated with insulin resistance
- Monitors patients with obesity, polycystic ovary syndrome (PCOS), or fatty liver disease
- Typically performed during a 2-hour glucose tolerance test (GTT) or oral glucose tolerance test (OGTT)
Normal Range
- Reference Values: • 2-hour postprandial insulin: Less than 140 mIU/mL (or <840 pmol/L) • Normal fasting insulin: 2-12 mIU/mL (or 12-84 pmol/L) • Optimal postprandial: Less than 100 mIU/mL indicates good glucose control
- Units of Measurement: • Primary: milli-International Units per milliliter (mIU/mL) • Alternative: picomoles per liter (pmol/L)
- Result Interpretation: • Normal/Negative: ≤140 mIU/mL - appropriate insulin response to glucose stimulus • Elevated: >140 mIU/mL - suggests insulin resistance or impaired insulin secretion • Borderline: 100-140 mIU/mL - intermediate response, may indicate early insulin resistance • Significantly Elevated: >200 mIU/mL - marked insulin resistance or beta cell dysfunction
- Normal vs. Abnormal: • Normal values indicate adequate pancreatic function and appropriate metabolic response to glucose • Abnormal values suggest pancreatic dysfunction, insulin resistance, or impending diabetes development
Interpretation
- Elevated Postprandial Insulin (>140 mIU/mL): • Indicates insulin resistance - tissues require more insulin to achieve normal glucose uptake • Suggests early metabolic dysfunction or prediabetic state • May indicate impending type 2 diabetes development • Associated with compensatory hyperinsulinemia by the pancreas
- Normal Postprandial Insulin (≤140 mIU/mL): • Demonstrates appropriate pancreatic response to glucose stimulus • Indicates good insulin sensitivity and normal metabolic function • Suggests low risk for immediate diabetes development • Associated with favorable cardiovascular risk profile
- Low Postprandial Insulin (<20 mIU/mL): • May indicate pancreatic beta cell dysfunction or insufficiency • Suggests inability to mount adequate insulin response to glucose • Could indicate advanced diabetes or pancreatic disease • Requires evaluation for type 1 diabetes or autoimmune pancreatic conditions
- Factors Affecting Results: • Body weight and obesity status - increased adiposity increases insulin resistance • Physical activity level - sedentary lifestyle increases insulin levels • Diet composition - high glycemic index foods promote higher insulin response • Medications - steroids, antipsychotics, beta-blockers can elevate insulin • Stress and cortisol levels - acute stress increases insulin secretion • Menstrual cycle phase - hormonal variations affect insulin sensitivity • Sleep quality and duration - poor sleep increases insulin resistance • Time of blood collection - must be exactly 2 hours after glucose load
- Clinical Significance: • Postprandial insulin is more sensitive than fasting insulin for detecting early insulin resistance • Elevated levels correlate strongly with metabolic syndrome components (hypertension, dyslipidemia) • Hyperinsulinemia is an independent cardiovascular risk factor • Results help guide intervention strategies - diet, exercise, pharmacotherapy • Useful for monitoring response to lifestyle modifications or insulin-sensitizing medications
Associated Organs
- Primary Organ Systems: • Pancreas - specifically beta cells in islets of Langerhans that produce and secrete insulin • Liver - primary target organ for insulin action and glucose metabolism regulation • Muscle tissue - major site of glucose utilization and insulin action • Adipose tissue - affected by insulin resistance and hyperinsulinemia
- Diseases Associated with Abnormal Results: • Type 2 Diabetes Mellitus - caused by progressive insulin resistance and beta cell dysfunction • Prediabetes - early stage characterized by elevated postprandial insulin and impaired glucose tolerance • Metabolic Syndrome - cluster of conditions including insulin resistance, hypertension, dyslipidemia • Polycystic Ovary Syndrome (PCOS) - characterized by insulin resistance and hyperinsulinemia • Nonalcoholic Fatty Liver Disease (NAFLD) - strongly associated with insulin resistance • Obesity - central pathophysiology involves insulin resistance • Cardiovascular Disease - insulin resistance is independent risk factor • Type 1 Diabetes - may show low insulin response indicating autoimmune beta cell destruction
- Potential Complications of Abnormal Results: • Progressive pancreatic beta cell exhaustion leading to overt diabetes • Increased risk of myocardial infarction and stroke from sustained hyperinsulinemia • Progression of NAFLD to cirrhosis and hepatic failure • Chronic kidney disease development and progression • Proliferation of atherosclerotic lesions and accelerated arterial disease • Diabetic retinopathy, neuropathy, and nephropathy if diabetes develops • Increased inflammation and oxidative stress throughout body systems
Follow-up Tests
- Recommended Follow-up Tests Based on Elevated Insulin PP: • Fasting Glucose - assess baseline glucose control • 2-Hour Postprandial Glucose - evaluate glucose response during OGTT • Hemoglobin A1C (HbA1c) - measure average blood glucose over preceding 2-3 months • Fasting Insulin - determine basal insulin secretion and HOMA-IR calculation • HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) - quantify degree of insulin resistance • Lipid Panel - evaluate cardiovascular risk (often abnormal with insulin resistance)
- Further Investigations for Specific Conditions: • For Prediabetes: Repeat OGTT annually, lifestyle intervention counseling • For PCOS: FSH, LH, testosterone, pelvic ultrasound • For NAFLD: Liver function tests, abdominal ultrasound, transient elastography • For Cardiovascular Risk: High-sensitivity CRP, homocysteine, lipoprotein(a) • For Renal Assessment: Creatinine, eGFR, urinary albumin-to-creatinine ratio
- Monitoring Frequency: • For Normal Results: Retest every 3-5 years in asymptomatic adults • For Prediabetic Range: Repeat testing annually or every 6 months • For Established Diabetes: Monitor via HbA1c every 3-6 months • During Weight Loss Program: Every 3 months to assess metabolic improvement • On Insulin-Sensitizing Medications: Every 6-12 months to evaluate treatment response
- Complementary Tests: • Glucose Tolerance Status - continuous glucose monitoring or CGM • Pancreatic Function - C-peptide level to assess endogenous insulin production • Metabolic Assessment - adiponectin, leptin for adipokine evaluation • Beta Cell Function - proinsulin levels if available • Insulinogenic Index - calculated from OGTT samples (insulin change/glucose change)
Fasting Required?
- Fasting Requirement: YES - Fasting is REQUIRED for this test
- Fasting Duration: • Minimum 8 hours of fasting before initial blood draw (baseline/fasting insulin) • Must consume standardized 75-gram glucose drink at baseline after fasting sample • Remain fasting for additional 2 hours until postprandial sample collection
- Dietary Instructions: • No food consumption from midnight before the test (overnight fast) • No eating for the 2-hour duration after glucose load • Water only permitted throughout fasting and test period • No alcohol for 24 hours before test • Avoid chewing gum (even sugarless) during fasting period • No smoking during fasting and test period if possible
- Medications to Avoid: • Insulin or insulin-sensitizing medications (metformin, thiazolidinediones) - discontinue 24 hours prior if medically safe • Corticosteroids - can increase insulin levels • Beta-blockers - may affect insulin secretion • Antipsychotics and certain antidepressants - can elevate insulin • Diuretics - may affect glucose and insulin metabolism • Consult physician regarding all medications - provide medication list at time of testing
- Additional Patient Preparation: • Maintain normal diet for 3 days before test (avoid unusually high or low carbohydrate intake) • Maintain regular physical activity patterns - avoid strenuous exercise day of test • Rest comfortably 15 minutes before baseline blood draw • Arrive well-hydrated but with empty bladder • Inform lab technician of any anxiety or vasovagal history • Bring insurance card and identification • Allow 2-3 hours total for complete OGTT procedure • Arrange transportation if concerned about lightheadedness or dizziness post-test

How our test process works!